Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related
Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.